Table 1.
Demographic and baseline clinical characteristics by treatment arm.
| Placebo (N = 15) | DHA (N = 18) | P-value | |
|---|---|---|---|
| Age in years, median (min, max) | 69 (58, 79) | 68.5 (58, 90) | 0.46 |
| Males, n (%) | 4 (27%) | 2 (11%) | 0.37 |
| Race, n (%) | 0.39 | ||
| White (Non-Hispanic) | 7 (47%) | 11 (61%) | |
| Hispanic | 5 (33%) | 6 (33%) | |
| Black | 0 | 1 (6%) | |
| Asian | 2 (13%) | 0 | |
| Other | 1 (7%) | 0 | |
| APOE genotype, n (%)a | 0.99 | ||
| E2/E3 | 2 (13%) | 3 (17%) | |
| E3/E3 | 6 (40%) | 6 (33%) | |
| E3/E4 | 6 (40%) | 6 (33%) | |
| E4/E4 | 1 (7%) | 2 (11%) | |
| BMI (kg/m2), median (IQR) | 32.0 (7.3) | 27.8 (5.8) | 0.13 |
| HgbA1c (%), median (IQR) | 5.7 (0.2) | 5.8 (0.6) | 0.66 |
| MoCA, median (min, max)b | 27 (22, 30) | 28 (19, 30) | 0.62 |
a
The exact genotype of one of the non-APOE4 carriers in the DHA arm was not determined.
b
Sample size for HgbA1c, MoCA: placebo (N = 15), DHA (N = 17).